14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
AGIO vs PTCT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Agios Pharmaceuticals, Inc. (AGIO) captures the overall head-to-head institutional edge over PTC Therapeutics, Inc. (PTCT) on higher Unified Composite conviction (58.1/100 HOLD vs. 44.5/100 HOLD) after splitting the core matrix 6–4 (led by Valuation Multiples, Options & Positioning), while PTCT wins 4–2 across the 6-pillar growth and valuation breakdown. AGIO trades at $30.42 (2.5x Forward P/E, -297.7% operating margin) versus PTCT at $61.62 (19.9x Forward P/E, 21.5% operating margin).
Growth vs. Quality Trade-Off: AGIO earns the overall head-to-head edge with a stronger Unified Composite Score (58.1/100 HOLD vs. PTCT 44.5/100 HOLD) and 1.12β · 85% Vol risk profile, whereas PTCT leads top-line expansion (+69.6% YoY revenue growth, 0.81x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: AGIO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.4); meanwhile PTCT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AGIO vs PTCT. Trailing 12-month operating profitability (AGIO -297.7% vs PTCT 21.5%) and valuation multiples (AGIO 2.5x vs PTCT 19.9x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $5.3B market capitalization and 21.5% operating margin.
OpEx & R&D Reinvestment33.7% of Rev ($389M)
90D Engineering Disclosures0 Published
Investor FAQ AGIO vs PTCT Key Questions & Quantitative Answers
As of Nov 16, 2026, Agios Pharmaceuticals, Inc. (AGIO) captures the overall head-to-head institutional edge over PTC Therapeutics, Inc. (PTCT) on higher Unified Composite conviction (58.1/100 HOLD vs. 44.5/100 HOLD) after splitting the core matrix 6–4 (led by Valuation Multiples, Options & Positioning), while PTCT wins 4–2 across the 6-pillar growth and valuation breakdown. AGIO trades at $30.42 (2.5x Forward P/E, -297.7% operating margin) versus PTCT at $61.62 (19.9x Forward P/E, 21.5% operating margin). Growth vs. Quality Trade-Off: AGIO earns the overall head-to-head edge with a stronger Unified Composite Score (58.1/100 HOLD vs. PTCT 44.5/100 HOLD) and 1.12β · 85% Vol risk profile, whereas PTCT leads top-line expansion (+69.6% YoY revenue growth, 0.81x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: AGIO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.4); meanwhile PTCT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
PTCT leads the Growth & Scale pillar: AGIO posts +330.0% YoY revenue growth and +0.0% YoY earnings growth on $141M TTM revenue (N/A gross margin, -297.7% operating margin), compared with PTCT at +69.6% YoY revenue growth and +0.0% YoY earnings growth on $1.16B TTM revenue (55.2% gross margin, 21.5% operating margin). On trailing 12-month operating scale, AGIO generates $141M in USD-normalized revenue versus $1.16B for PTCT. In operating R&D and SG&A reinvestment, AGIO deploys N/A (0 90-day corporate R&D disclosures) versus 33.7% of Rev ($389M) (0 disclosures) for PTCT.
AGIO screens cheaper on headline valuation multiples. AGIO trades at 2.5x Forward P/E, 2.5x Trailing P/E, N/M PEG, and 13.5x EV/Revenue (unreported EBITDA margin), whereas PTCT trades at 19.9x Forward P/E, 19.4x Trailing P/E, 0.81x PEG, and 4.7x EV/Revenue (-3.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AGIO (-33.0% ROE) versus PTCT (-7740.1% ROE) capital efficiency.
In options market volatility and institutional positioning, AGIO carries 65.7% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.12β · 85% Vol realized risk). By comparison, PTCT carries 55.7% implied volatility (17th %ile, Compressed (<25th %ile)), a 0.18x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.81β · 58% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.